OncoZenge Management
Management criteria checks 1/4
OncoZenge's CEO is Stian Kildal, appointed in Sep 2023, has a tenure of 2.75 years. total yearly compensation is SEK1.67M, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 3.56% of the company’s shares, worth €289.39K. The average tenure of the management team and the board of directors is 1.8 years and 2.4 years respectively.
Key information
Stian Kildal
Chief executive officer
SEK 1.7m
Total compensation
| CEO salary percentage | 100.00% |
| CEO tenure | 2.8yrs |
| CEO ownership | 3.6% |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.4yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -SEK 23m |
| Dec 31 2025 | SEK 2m | SEK 2m | -SEK 16m |
| Sep 30 2025 | n/a | n/a | -SEK 9m |
| Jun 30 2025 | n/a | n/a | -SEK 7m |
| Mar 31 2025 | n/a | n/a | -SEK 6m |
| Dec 31 2024 | SEK 902k | SEK 902k | -SEK 9m |
Compensation vs Market: Stian's total compensation ($USD176.59K) is below average for companies of similar size in the German market ($USD432.82K).
Compensation vs Earnings: Stian's compensation has increased whilst the company is unprofitable.
CEO
Stian Kildal (50 yo)
Mr. Stian Kildal is Chief Executive Officer of OncoZenge AB (publ) from September 13, 2023.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 2.8yrs | SEK 1.67m | 3.56% € 289.4k | |
| Chief Financial Officer | 3.4yrs | no data | 0.071% € 5.8k | |
| Chief Auditor | no data | no data | no data | |
| Head of CMC in Phase 3 Sponsor Team | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: 8LY's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Member of Advisory Board | 2.5yrs | no data | no data | |
| Member of Advisory Board | less than a year | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Independent Director | 2.4yrs | no data | 0.19% € 15.6k | |
| Member of Advisory Board | 2.5yrs | no data | no data | |
| Independent Chairman of the Board | 2.4yrs | no data | no data | |
| Member of the Advisory Board | 2.2yrs | no data | no data |
Experienced Board: 8LY's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/07 12:19 |
| End of Day Share Price | 2026/06/05 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OncoZenge AB (publ) is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fredrik Thor | Redeye |
| Kevin Sule | Redeye |
| Johan Unnerus | Redeye |